Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia

Launched by APPLIED BIOLOGY, INC. · Jan 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called DA-007 to help women who experience hair loss due to chemotherapy, a condition known as chemotherapy-induced alopecia. The trial is specifically looking at women between the ages of 18 and 65 who have been diagnosed with stage I or II breast cancer and are scheduled to start at least four cycles of a specific type of chemotherapy.

If eligible, participants will take DA-007 while they undergo their chemotherapy treatment. The goal is to see if this medication can help reduce or prevent hair loss. It's important to note that some women may not be able to participate if they have certain health conditions, like severe high blood pressure or other scalp issues. This trial is not yet recruiting participants, so if you or someone you know might be interested, keep an eye out for updates!

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with stage I or stage II breast cancer
• • Scheduled but not begun, at least 4 cycles of taxane and/or anthracycline-based chemotherapy.
• • Ages 18-65
• • Able to give informed consent
• Exclusion Criteria:
• • Resting blood pressure outside the range of 105-140/ 55-99
• • Uncontrolled or severe hypertension
• • Female pattern hair loss or hair loss disorder
• • Folliculitis
• • Scalp psoriasis
• • Seborrheic dermatitis
• • Inflammatory scalp conditions such as lichen planopillaris
• • Subjects wearing wigs prior to chemotherapy
• • Use of MAO inhibitors
• • Unable to provide consent or make allotted clinical visits